Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Sagimet Biosciences Inc. announced the approval of inducement grants of 42,800 stock options to three newly-hired employees as part of their employment compensation [1][2] - The stock options will have an exercise price based on the closing price of Sagimet's Series A common stock on December 9, 2025, and will vest over a four-year period [3] Company Overview - Sagimet is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors to address dysfunctional metabolic and fibrotic pathways, particularly related to the overproduction of palmitate [4] - The company’s lead product, denifanstat, has shown positive results in clinical trials for metabolic dysfunction associated steatohepatitis (MASH) and is also being tested in combination with resmetirom for cirrhotic patients with F4-stage MASH [4] - Another product, TVB-3567, is currently undergoing a Phase 1 first-in-human clinical trial for acne treatment [4]